Oxford BioDynamics (LON:OBD) Hits New 12-Month Low – Here’s Why

Oxford BioDynamics Plc (LON:OBD)’s stock price hit a new 52-week low on Monday . The stock traded as low as GBX 0.45 ($0.01) and last traded at GBX 0.48 ($0.01), with a volume of 6010472 shares trading hands. The stock had previously closed at GBX 0.50 ($0.01).

Analysts Set New Price Targets

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a report on Thursday, March 13th.

Oxford BioDynamics Price Performance

The company has a current ratio of 0.68, a quick ratio of 2.80 and a debt-to-equity ratio of 370.22. The company’s 50 day moving average is GBX 0.53 and its 200-day moving average is GBX 1.34. The stock has a market cap of £8.96 million, a PE ratio of -0.08 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.